The Saudi pharmaceutical market is the largest in the GCC region. The vast majority of the market is comprised of imports.
Many foreign companies have been entering the Kingdom of the Saudi Arabia drug market because of its pricing structure
and rapid approval processes. Additionally, private and public are operate under no tax policies. The government supports the
regulation and the drug traffic through (SFDA), which was established by Saudi Authorities in 2003. The SFDA intended to
provide high quality medicine for the fast growing population. As of 2012 Saudi drug market size is expected to improve its
annual growth of 4.74%, which estimated to reach SAR13.1 billion ($3.49 billion) by the end of this year. Local manufactures
supplied only 16% of the total pharmaceutical market. Imported pharmaceuticals which occupy the 84%, from foreign countries
are estimated to grow by 5.25% and projected to reach $2.88 billion this year. There are currently about 5,700 registered drugs sold
through more than 4,500 pharmacies through the country. Saudi government is planning to improve the local pharmaceutical
industry through R&D. Cultural revolution and utilization of high technologies are the first necessary steps for Saudi pharma
to build the R&D engine. The plan includes joining the intellectual efforts with technology transferee professionals and building
an effective postgraduate program with postdoctoral training. The country plan also involves establishing ?university-industrygovernment
triumvirate? as a normative innovation network.
Rezk is the founder of the clinical pharmacology and analytical chemistry core laboratory at University of North Carolina at Chapel Hill. Honors
include; the UNC Chancellor?s award for innovation, and the State of North Carolina Governor?s award for innovation in science. He acts as the
PI for many HIV-research projects. Dr. Rezk published 36 papers in reputed journals and 32 scientific abstracts. Currently, Dr. Rezk is in charge
of developing BE/BA unit and clinical pharmacology research center in KSA. His research interests include innovation in analytical chemistry and
clinical pharmacology. Recently, he has added a focus on better laboratory science practice for improving generic drugs.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals